• Supreme Court to Review Statistical Significance Standards in Connection with § 10b-5 Claims
  • July 2, 2010 | Authors: Phillip A. Geraci; William E. Wallace
  • Law Firm: Kaye Scholer LLP - New York Office
  • On June 14, 2010, the U.S. Supreme Court agreed to decide whether a plaintiff can state a claim under § 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 based on a pharmaceutical company’s non-disclosure of adverse event reports, even when those reports are not alleged to be statistically significant.